Business

Sensorion Releases Full Year 2023 Financial Report

Sensorion (ALSEN) (Paris:ALSEN), a pioneering clinical-stage biotechnology company specializing in developing innovative therapies for hearing loss disorders, announces the availability of its Full Year 2023 Financial Report. This comprehensive report has been officially filed with the Autorité des marchés financiers (AMF) and contains essential financial information for the year 2023.

Contents of the Financial Report

The Financial Report for 2023 encompasses the following key components:

Management Report: Provides insights into Sen sorion’s operational performance, strategic initiatives, and future outlook.

Annual Accounts and Financial Statements: Presents a detailed overview of Sen sorion’s financial position, including balance sheets, income statements, and cash flow statements.

Information on Auditor Fees: Discloses the fees paid to the Statutory Auditors for their services related to the auditing of the 2023 accounts.

Accessing the Financial Report

The Annual Financial Report for 2023 is now available for public access through the following channels:

Sen sorion’s Website: The report can be found in the Financial Information section of Sens orion’s official website at www.sensorion.com.

Mega Millions Jackpot Soars to $875 Million

AMF Website: Additionally, the report is accessible on the AMF’s website at www.amf-france.org.

Obtaining a Copy
Members of the public can obtain a copy of the Financial Report, free of charge, through the following means:

Company Headquarters: Visit Sensorion’s headquarters located at 375 rue du Professeur Joseph Blayac, 34080 Montpellier, France.

About Sensorion

Sensorion is at the forefront of developing innovative therapies to address the significant global challenge of hearing loss disorders. Leveraging its advanced R&D technology platform, Sensorion focuses on understanding the underlying causes of inner ear diseases to identify optimal targets and treatment mechanisms.

The company’s portfolio includes gene therapy programs targeting hereditary forms of deafness, such as SENS-501 (OTOF-GT) and GJB2-GT, along with clinical-stage small molecule programs like SENS-401 (Arazasetron). With a commitment to advancing hearing loss treatment and prevention, Sensorion aims to make a meaningful impact on patients’ lives worldwide.

Allen

Allen holds a Master's degree in English Literature and boasts seven years of experience as a content writer. Specializing in Entertainment, Sports, and the latest news, he excels in crafting compelling narratives that captivate audiences. Allen's expertise in language and storytelling ensures that his content is both informative and engaging.

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button